Engineered iPSCs and immune effector cells for heterogeneous tumor control

JP2023548829A5Inactive Publication Date: 2024-11-12FATE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526091
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-04-09
Filing Date
2021-11-04
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

Methods and compositions are provided for obtaining functionally enhanced derived effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived effector cells provided herein have stable, functional genome editing that results in improved or enhanced therapeutic efficacy. Therapeutic compositions and uses thereof are also provided, comprising the functionally enhanced derived effector cells alone or in combination with antibodies or checkpoint inhibitors in combination therapy.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A cell or population thereof, wherein the cell comprises a polynucleotide encoding a CAR that targets a B7H3 tumor antigen, the CAR comprising: (i) an amino acid sequence that is at least about 99%, 98%, 96%, 95%, 90%, 85%, or 80% identical to SEQ ID NO: 36, 37, 38, 39, 40, or 41; (ii) an amino acid sequence represented by a variant of SEQ ID NO: 36, said variant having one or more mutations at positions including 1, 40, 46, 79, 87, 88, 89, 97, 98, and 117 of SEQ ID NO: 36; (iii) an amino acid sequence represented by a variant of SEQ ID NO: 36, said variant having one or more substitutions according to SEQ ID NO: 36, including Q1E, T40A, E46V, G79L, K87R, P88A, D89E, V97A, S98R, and Q117L; or (iv) a binding domain comprising an amino acid sequence represented by any of SEQ ID NOs: 36, 37, 38, 39, 40, and 41; The cell or population thereof, wherein the cell is a eukaryotic cell, an animal cell, a human cell, an immune cell, an induced pluripotent cell (iPSC), or a derived cell differentiated therefrom.

2. 2. The cell or population thereof of claim 1, wherein the cell further comprises one or more polynucleotides encoding an engager, and optionally a CFR (chimeric fusion receptor), and the engager has a tumor antigen targeting specificity that is not B7H3.

3. (i) the engager is selected from the group consisting of ADGRE2, carbonic anhydrase IX (CAIX), CCR1, CCR4, carcinoembryonic antigen (CEA), CD3, CD5, CD7, CD8, CD10, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CDS, CLEC12A, an antigen of cytomegalovirus (CMV)-infected cells, and epithelial glycoprotein. epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), EGFRvIII, receptor tyrosine-protein kinase erb-B2, 3, 4, EGFIR, EGFR-VIII, ERBB folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase hTERT, ICAM-1, integrin B7, interleukin-13 receptor subunit alpha-2 (IL-13Rα2), kappa-light chain, kinase insert domain receptor (KDR), Lewis A (CA19.9), Lewis Y (LeY), L1 cell adhesion molecule (L1-CAM), LILRB2, melanoma antigen family A1 (MAGE-A1), MICA / B, MR1, mucin 1 (Muc-1), mucin 16 (Muc-16), mesothelin (MSLN), NKCSI, a first binding domain with tumor-targeting specificity for any one of NKG2D ligand, c-Met, NY-ESO-1, oncofetal antigen (h5T4), PDL1, PRAME, prostate stem cell antigen (PSCA), PRAME prostate specific membrane antigen (PSMA), tumor associated glycoprotein 72 (TAG-72), TIM-3, TRBC1, TRBC2, vascular endothelial growth factor R2 (VEGF-R2), Wilms tumor protein (WT-1), and a pathogen antigen; (ii) the engager comprises a second binding domain having a specificity which is different to the specificity of the first binding domain and which is for the extracellular portion of CD3, CD28, CD5, CD16, CD64, CD32, CD33, CD89, NKG2C, NKG2D, or a functional variant of any thereof, or the second binding domain of the engager is specific for the ectodomain of the CFR; or (iii) the engager comprises a cytokine or a variant thereof between the first binding domain and the second binding domain, the cytokine comprising at least one of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, and IL21.

4. (i) the CFR comprises an ectodomain fused to a transmembrane domain, the transmembrane domain being operably connected to an endodomain, and the ectodomain, the transmembrane domain and the endodomain do not comprise any endoplasmic reticulum (ER) retention or endocytosis signals; or (ii) the CFR comprises an ectodomain comprising the full length or a partial length of the extracellular portion of a signaling protein comprising at least one of CD3ε, CD3γ, CD3δ, CD28, CD5, CD16, CD64, CD32, CD33, CD89, NKG2C, NKG2D, any functional variant thereof, and combinations or chimeras thereof; (iii) the CFR comprises an ectodomain that initiates signal transduction upon binding to a selected agonist; (iv) the CFR comprises an endodomain comprising a cytotoxic domain comprising at least the entire length or a portion of a CD3ζ, 2B4, DAP10, DAP12, DNAM1, CD137 (4-1BB), IL21, IL7, IL12, IL15, NKp30, NKp44, NKp46, NKG2C, or NKG2D polypeptide, and optionally the endodomain comprises (a) a costimulatory domain comprising a full length or portion of a CD2, CD27, CD28, CD40L, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, or NKG2D polypeptide, or any combination thereof; (b) a costimulatory domain comprising the full length or a portion of CD28, 4-1BB, CD27, CD40L, ICOS, CD2, or any combination thereof; (c) a sustained signaling domain comprising the entire length or a portion of the internal domain of a cytokine receptor, including IL7R, IL15R, IL18R, IL12R, IL23R, or a combination thereof; and / or (d) further comprising one or more of a complete or partial intracellular portion of a receptor tyrosine kinase (RTK), a tumor necrosis factor receptor (TNFR), an EGFR, or an FAS receptor; or (iv) the cell or population thereof of claim 2, wherein the CFR is co-expressed with the engager or the CAR, either in a separate construct or in a bicistronic expression cassette.

5. The cells, compared to their corresponding primary cells, (i) CD38 knockout, (ii) HLA-I deficiency and / or HLA-II deficiency, (iii) introduction of HLA-G or non-cleavable HLA-G, or knockout of either or both of CD58 and CD54; (iv) exogenous CD16 or a variant thereof; (v) signaling complexes comprising partial or complete peptides of cell surface expressed exogenous cytokines and / or their receptors; (vi) at least one of the genotypes listed in Table 1; (vii) disruption of at least one of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, TCR, NKG2A, NKG2D, CD25, CD69, CD44, CD56, CIS, CBL-B, SOCS2, PD1, CTLA4, LAG3, TIM3, and TIGIT; or (viii) HLA-E, 4-1BBL, CD3, CD4, CD8, CD16, CD47, CD113, CD131, CD137, CD80, PDL1, A 2A The cell or population thereof of any one of claims 1 to 4, further comprising one or more of the following: an antigen-specific TCR, an Fc receptor, an antibody or a functional variant or fragment thereof, a checkpoint inhibitor, and introduction of at least one of a surface triggering receptor for coupling with an agonist.

6. The cells are compared to their corresponding primary cells obtained from peripheral blood, umbilical cord blood, or any other donor tissue, (i) increased cytotoxicity, (ii) improved persistence and / or survival; (iii) an enhanced ability to migrate and / or activate or recruit bystander immune cells to the tumor site; (iv) improved tumor penetration; (v) enhanced ability to reduce tumor immunosuppression; (vi) improved ability to rescue tumor antigen escape; (vii) regulated apoptosis; (viii) enhanced or gained ADCC, and (ix) the ability to avoid fratricide; The cell or population thereof according to any one of claims 1 to 5, having therapeutic properties including at least one of the above.

7. The exogenous CD16 or a variant thereof (a) high affinity non-cleavable CD16 (hnCD16); (b) F176V and S197P in the ectodomain of CD16; (c) a complete or partial ectodomain derived from CD64; (d) a non-native (or non-CD16) transmembrane domain; (e) a non-native (or non-CD16) intracellular domain; (f) a non-native (or non-CD16) signaling domain; (g) a non-naturally occurring stimulatory domain, and (h) the cell or population thereof described in claim 6, comprising at least one of a transmembrane domain, a signaling domain, and a stimulatory domain that are not derived from CD16 and are derived from the same or a different polypeptide.

8. The cell surface expressed exogenous cytokine or its receptor, (a) at least one of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, IL21, and their respective receptors; or (b) (i) Co-expression of IL15 and IL15Rα by using a self-cleaving peptide; (ii) a fusion protein of IL15 and IL15Rα; (iii) an IL15 / IL15Rα fusion protein in which the intracellular domain of IL15Rα has been truncated or eliminated; (iv) a fusion protein of IL15 and the membrane-binding Sushi domain of IL15Rα; (v) a fusion protein of IL15 and IL15Rβ; (vi) a fusion protein of IL15 and common receptor γC, said common receptor γC being natural or modified; and (vii) a homodimer of IL15Rβ; (b) any one of (i)-(vii) is optionally co-expressed with the CAR, either in a separate construct or in a bicistronic construct; or (c) (i) a fusion protein of IL7 and IL7Rα; (ii) a fusion protein of IL7 and common receptor γC, wherein the common receptor γC is natural or modified; and (iii) a homodimer of IL7Rβ; and (c) any one of (i)-(iii) is optionally co-expressed with the CAR in a separate construct or in a bicistronic expression cassette; Optionally, (d) The cell or population thereof described in claim 7, which is transiently expressed.

9. The checkpoint inhibitor is selected from the group consisting of PD-1, PDL-1, TIM-3, TIGIT, LAG-3, CTLA-4, 2B4, 4-1BB, 4-1BBL, A 2A 8. The cell or population thereof of claim 7, which is an antagonist to one or more checkpoint molecules including R, BATE, BTLA, CD39, CD47, CD73, CD94, CD96, CD160, CD200, CD200R, CD274, CEACAM1, CSF-1R, Foxp1, GARP, HVEM, IDO, EDO, TDO, LAIR-1, MICA / B, NR4A2, MAFB, OCT-2, Rara (retinoic acid receptor alpha), TLR3, VISTA, NKG2A / HLA-E, and inhibitory KIR.

10. The cells, (i) one or more exogenous polynucleotides integrated into a safe harbor locus or a selected locus; or (ii) more than two exogenous polynucleotides integrated into different safe harbor loci or two or more selected loci.

11. 11. The cell or population thereof of claim 10, wherein the safe harbor locus comprises at least one of AAVS1, CCR5, ROSA26, collagen, HTRP, H11, GAPDH, or RUNX1, and the selected locus is one of B2M, TAP1, TAP2, tapasin, NLRC5, CIITA, RFXANK, RFX5, RFXAP, TCR, NKG2A, NKG2D, CD38, CD25, CD69, CD44, CD58, CD54, CD56, CIS, CBL-B, SOCS2, PD1, CTLA4, LAG3, TIM3, or TIGIT, and / or the integration of the exogenous polynucleotide knocks out expression of the gene at the locus.

12. The cell or population thereof according to claim 11 , wherein the TCR locus is the constant region of TCR alpha and / or TCR beta (TRAC and / or TRBC).

13. The iPSCs are clonal iPSCs, single cell dissociated iPSCs, iPSC cell line cells, or iPSC Master Cell Bank (MCB) cells, or the derived cells are derived CD34 + 2. The cell or population thereof of claim 1, comprising a derived hematopoietic stem progenitor cell, a derived hematopoietic multipotent progenitor cell, a derived T cell precursor, a derived NK cell precursor, a derived T lineage cell, a derived NKT lineage cell, a derived NK lineage cell, a derived B lineage cell, or a derived effector cell having one or more functional traits not present in the corresponding primary T, NK, NKT, and / or B cell.

14. A composition comprising a cell or a population thereof according to any one of claims 1 to 13.

15. A composition comprising a derived cell according to any one of claims 1 to 13 and one or more therapeutic agents.

16. 16. The composition of claim 15, wherein the one or more therapeutic agents comprise a peptide, a cytokine, a checkpoint inhibitor, a mitogen, a growth factor, a small RNA, a dsRNA (double stranded RNA), a mononuclear blood cell, a feeder cell, a feeder cell component or a supplement thereof, a vector comprising one or more polynucleic acids of interest, an antibody, a chemotherapeutic agent or a radioactive moiety, or an immunomodulatory drug (IMiD).

17. (i) the checkpoint inhibitor is (a) PD-1, PDL-1, TIM-3, TIGIT, LAG-3, CTLA-4, 2B4, 4-1BB, 4-1BBL, A 2A one or more antagonists against checkpoint molecules, including R, BATE, BTLA, CD39, CD47, CD73, CD94, CD96, CD160, CD200, CD200R, CD274, CEACAM1, CSF-1R, Foxpl, GARP, HVEM, IDO, EDO, TDO, LAIR-1, MICA / B, NR4A2, MAFB, OCT-2, Rara (retinoic acid receptor alpha), TLR3, VISTA, NKG2A / HLA-E, or inhibitory KIR; (b) one or more of atezolizumab, avelumab, durvalumab, ipilimumab, IPH4102, IPH43, IPH33, lilimumab, monalizumab, nivolumab, pembrolizumab, and derivatives or functional equivalents thereof; (c) at least one of atezolizumab, nivolumab, and pembrolizumab; or (ii) The composition of claim 16, wherein the therapeutic agent comprises one or more of venetoclax, azacitidine, and pomalidomide.

18. The antibody, (a) anti-CD20, anti-HER2, anti-CD52, anti-EGFR, anti-CD123, anti-GD2, anti-PDL1, and / or anti-CD38 antibody, (b) one or more of rituximab, veltuzumab, ofatumumab, ublituximab, ocaratuzumab, obinutuzumab, trastuzumab, pertuzumab, alemtuzumab, cetuximab, dinutuximab, avelumab, daratumumab, isatuximab, MOR202, 7G3, CSL362, elotuzumab, and humanized or Fc-modified variants or fragments thereof, and functional equivalents and biosimilars thereof; or 17. The composition of claim 16, wherein (c) the composition comprises daratumumab, and the derived hematopoietic cells comprise derived NK cells or derived T cells comprising a CD38 knockout and optionally expression of exogenous CD16 or a variant thereof.

19. Use of a composition according to any one of claims 14 to 18 for the manufacture of a medicament for the treatment of an autoimmune disorder, a hematological malignancy, a solid tumor, cancer, or a viral infection.

20. 1. A composition comprising a cell or population thereof, wherein the cell comprises one or more polynucleotides encoding a chimeric antigen receptor (CAR), an engager, and optionally a CFR (chimeric fusion receptor), the CFR optionally being for engager coupling, and the cell is a eukaryotic cell, an animal cell, a human cell, an immune cell, an induced pluripotent cell (iPSC), or a differentiated derivative thereof.

21. The CAR is (i) an antigen recognition region specific for B7H3; (ii) a binding domain comprising an amino acid sequence that is at least about 99%, 98%, 96%, 95%, 90%, 85%, or 80% identical to SEQ ID NO: 36, 37, 38, 39, 40, or 41; (iii) a binding domain comprising an amino acid sequence represented by a variant of SEQ ID NO: 36, said variant having one or more mutations at positions including 1, 40, 46, 79, 87, 88, 89, 97, 98, and 117 of SEQ ID NO: 36; (iv) a binding domain comprising an amino acid sequence represented by a variant of SEQ ID NO: 36, said variant having one or more substitutions according to SEQ ID NO: 36, including Q1E, T40A, E46V, G79L, K87R, P88A, D89E, V97A, S98R, and Q117L; or (v) a binding domain comprising an amino acid sequence represented by any of SEQ ID NOs: 36, 37, 38, 39, 40, and 41.

22. The composition of claim 20 or 21, wherein the CFR comprises an ectodomain fused to a transmembrane domain, the transmembrane domain being operably connected to an endodomain, and the ectodomain, the transmembrane domain, and the endodomain do not comprise any endoplasmic reticulum (ER) retention or endocytosis signals.

23. (i) the ectodomain of the CFR comprises a full length or partial length of the extracellular portion of a signaling protein comprising at least one of CD3ε, CD3γ, CD3δ, CD28, CD5, CD16, CD64, CD32, CD33, CD89, NKG2C, NKG2D, any functional variant thereof, and combinations or chimeras thereof; (ii) the ectodomain of the CFR initiates signal transduction upon binding to a selected agonist; (iii) the endodomain of the CFR comprises a cytotoxic domain comprising at least the entire length or a portion of a CD3ζ, 2B4, DAP10, DAP12, DNAM1, CD137 (4-1BB), IL21, IL7, IL12, IL15, NKp30, NKp44, NKp46, NKG2C, or NKG2D polypeptide, and optionally the endodomain comprises (a) a costimulatory domain comprising a full length or portion of a CD2, CD27, CD28, CD40L, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, or NKG2D polypeptide, or any combination thereof; (b) a costimulatory domain comprising the full length or a portion of CD28, 4-1BB, CD27, CD40L, ICOS, CD2, or a combination thereof; (c) a sustained signaling domain comprising the entire length or a portion of the internal domain of a cytokine receptor, including IL7R, IL15R, IL18R, IL12R, IL23R, or a combination thereof; and / or (d) further comprising one or more of a complete or partial intracellular portion of a receptor tyrosine kinase (RTK), a tumor necrosis factor receptor (TNFR), an EGFR, or an FAS receptor; or (iv) the CFR is co-expressed with the engager, either in a separate construct or in a bicistronic expression cassette, and optionally the engager has binding specificity for the ectodomain of the CFR.

24. the selected agonist is (i) an antibody or a functional variant or fragment thereof, (ii) an agonist ligand, or (iii) an engager; The selected agonist is (a) encoded by the polynucleotide contained in the cell of the composition or contained in the composition; (b) at least a first binding domain specific for at least one tumor antigen comprising B7H3, CD10, CD19, CD20, CD22, CD24, CD30, CD33, CD34, CD38, CD44, CD79a, CD79b, CD123, CD138, CD179b, CEA, CLEC12A, CS-1, DLL3, EGFR, EGFRvIII, EpCAM, FLT-3, FOLR1, FOLR3, GD2, gpA33, HER2, HM1.24, LGR5, MSLN, MCSP, MICA / B, PSMA, PAMA, P-cadherin, or ROR1, and optionally (c) (1) the cell of the composition, or (2) a second binding domain specific for a cell surface protein of a bystander effector cell; 24. The composition of claim 23, wherein the cell surface protein comprises an extracellular portion of CD3, CD28, CD5, CD16, CD64, CD32, CD33, CD89, NKG2C, NKG2D, or any functional variant thereof.

25. 1. A method of producing a derivative effector cell comprising a first polynucleotide encoding a chimeric antigen receptor (CAR) and one or more additional polynucleotides encoding an engager and / or a CFR, wherein the engager has a distinct tumor targeting specificity from the CAR, the method comprising: and differentiating the engineered iPSCs, wherein the iPSCs have a specific function in the expression of the first polynucleotide and the one or more additional polynucleotides, and optionally a specific function in the expression of the first polynucleotide and the one or more additional polynucleotides, as compared to their corresponding primary cells. (i) CD38 knockout, (ii) HLA-I deficiency and / or HLA-II deficiency, (iii) introduction of HLA-G or non-cleavable HLA-G, or knockout of either or both of CD58 and CD54; (iv) exogenous CD16 or a variant thereof; (v) chimeric antigen receptor (CFR), (vi) inactivated CAR; (vii) partial or complete peptides of cell surface expressed exogenous cytokines and / or their receptors; (viii) at least one of the genotypes listed in Table 1; (ix) disruption of at least one of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, TCR, NKG2A, NKG2D, CD25, CD69, CD44, CD56, CIS, CBL-B, SOCS2, PD1, CTLA4, LAG3, TIM3, and TIGIT; or (x) HLA-E, 4-1BBL, CD3, CD4, CD8, CD16, CD47, CD113, CD131, CD137, CD80, PDL1, A 2A and introduction of at least one of an R, an antigen-specific TCR, an Fc receptor, an antibody or functional variant or fragment thereof, a checkpoint inhibitor, and a surface triggering receptor for coupling to an agonist.

26. 26. The method of claim 25, wherein the CAR comprises an antigen recognition region specific for B7H3.

27. 26. The method of claim 25, wherein the CFR comprises an ectodomain fused to a transmembrane domain, the transmembrane domain being operably connected to an endodomain, and the ectodomain, the transmembrane domain, and the endodomain do not comprise any endoplasmic reticulum (ER) retention or endocytosis signals.

28. (i) the ectodomain of the CFR comprises a full length or partial length of the extracellular portion of a signaling protein comprising at least one of CD3ε, CD3γ, CD3δ, CD28, CD5, CD16, CD64, CD32, CD33, CD89, NKG2C, NKG2D, any functional variant thereof, and combinations or chimeras thereof; (ii) the ectodomain of the CFR initiates signal transduction upon binding to a selected agonist; or (iii) the endodomain of the CFR comprises a cytotoxic domain comprising at least the entire length or a portion of a CD3ζ, 2B4, DAP10, DAP12, DNAM1, CD137 (4-1BB), IL21, IL7, IL12, IL15, NKp30, NKp44, NKp46, NKG2C, or NKG2D polypeptide, and optionally the endodomain comprises (a) a costimulatory domain comprising a full length or portion of a CD2, CD27, CD28, CD40L, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, or NKG2D polypeptide, or any combination thereof; (b) a costimulatory domain comprising the full length or a portion of CD28, 4-1BB, CD27, CD40L, ICOS, CD2, or a combination thereof; (c) a sustained signaling domain comprising the entire length or a portion of the internal domain of a cytokine receptor, including IL7R, IL15R, IL18R, IL12R, IL23R, or a combination thereof; and / or 28. The method of claim 27, further comprising one or more of: (d) a complete or partial intracellular portion of a receptor tyrosine kinase (RTK), a tumor necrosis factor receptor (TNFR), an EGFR, or a FAS receptor.

29. the selected agonist is (i) an antibody or a functional variant or fragment thereof, (ii) an agonist ligand, or (iii) an engager; The selected agonist is (a) encoded by the polynucleotide contained in the cell of the composition or contained in the composition; (b) at least a first binding domain specific for at least one tumor antigen comprising B7H3, CD10, CD19, CD20, CD22, CD24, CD30, CD33, CD34, CD38, CD44, CD79a, CD79b, CD123, CD138, CD179b, CEA, CLEC12A, CS-1, DLL3, EGFR, EGFRvIII, EpCAM, FLT-3, FOLR1, FOLR3, GD2, gpA33, HER2, HM1.24, LGR5, MSLN, MCSP, MICA / B, PSMA, PAMA, P-cadherin, or ROR1, and optionally (c) (1) the cell of the composition, or (2) a second binding domain specific for a cell surface protein of a bystander effector cell; 29. The method of claim 28, wherein the cell surface protein comprises the extracellular portion of CD3, CD28, CD5, CD16, CD64, CD32, CD33, CD89, NKG2C, NKG2D, or any functional variant thereof.

30. A composition according to any one of claims 20 to 24 for treating a tumor in a subject, optionally wherein the tumor is a solid tumor or the tumor is heterologous.

31. A chimeric antigen receptor (CAR) comprising a binding domain, the binding domain comprising: (i) an amino acid sequence that is at least about 99%, 98%, 96%, 95%, 90%, 85%, or 80% identical to SEQ ID NO: 36, 37, 38, 39, 40, or 41; (ii) an amino acid sequence represented by a variant of SEQ ID NO: 36, said variant having one or more mutations at positions including 1, 40, 46, 79, 87, 88, 89, 97, 98, and 117 of SEQ ID NO: 36; (iii) an amino acid sequence represented by a variant of SEQ ID NO: 36, said variant having one or more substitutions according to SEQ ID NO: 36, including Q1E, T40A, E46V, G79L, K87R, P88A, D89E, V97A, S98R, and Q117L; or (iv) A chimeric antigen receptor (CAR) comprising an amino acid sequence represented by any of SEQ ID NOs: 36, 37, 38, 39, 40, and 41.

32. The CAR of claim 31, further comprising a hinge peptide comprising 80 or fewer amino acids, or comprising 80 to 180 amino acids, or comprising 229 or fewer amino acids.

33. The CAR has the following characteristics: (i) being T cell specific; (ii) being NK cell specific; (iii) binding to tumor cell surface B7H3; (iv) reducing tumor cell surface shedding of B7H3 antigen; or (v) increasing tumor cell surface B7H3 density.

34. When the CAR is expressed in an effector cell, the effector cell has the following characteristics: (i) enhancing effector cell activation and killing function compared to corresponding effector cells lacking the chimeric receptor; and (ii) is capable of controlling tumor progression in vivo, reducing tumor cell burden, tumor clearance, and / or improving survival of a subject bearing the tumor, as compared to a corresponding cell lacking the chimeric receptor.

35. 35. A method of producing a derivative cell comprising a polynucleotide encoding the CAR of any one of claims 31 to 34, comprising differentiating iPSCs to obtain said derivative cell, wherein the polynucleotide encoding the CAR is introduced into the iPSCs prior to differentiation or is introduced into the derivative cell following iPSC differentiation.

36. A composition according to any one of claims 14 to 18 and 20 to 24 for treatment.